Clofentezine, a growth inhibitor, has sublethal effects on life-table parameters of Tetranychus urticae Koch females.

Clopidogrel (Plavix) is an oral, thienopyridine class antiplatelet agent.

Cloquintocet-mexyl is a herbicide, used to control coarse annual grass of the family poaceae (gramineae).

Clozapine N-oxide is a major metabolite of Clozapine noted to decrease SR-2A (5-HT2 serotonin receptor) density in vitro.

CLP290 (CLP-290) is an orally acirtve small molecule K+-Cl- cotransporter isotype 2 (KCC2) activator, the carbamate prodrug of CLP257; In vivo co-treatment with morphine and oral CLP290 prevented membrane KCC2 downregulation in SDH neurons. Concurrently, co-treatment with CLP290 significantly mitigated MIH and acute administration of CLP257 in established MIH restored normal nociceptive behavior.

ClpP inhibitor M21 is a noncompetitive inhibitor of ClpP with IC50 of 41.42 uM, inhibits ClpP cleavage of SUc-LY-AMC substrate in a peptidase assay.

CLSP37 (RIPK2 inhibitor CLSP37) is a novel potent, ATP pocket-binding RIPK2 inhibitor with IC50 of 16.3 nM in ADPGlo assay, demonstrates inhibition of both the RIPK2-XIAP interaction, and of cellular and in vivo NOD2 signaling.

CLSP43 (RIPK2 inhibitor CLSP43) is a novel potent, ATP pocket-binding RIPK2 inhibitor with IC50 of 19.9 nM in ADPGlo assay, demonstrates inhibition of both the RIPK2-XIAP interaction, and of cellular and in vivo NOD2 signaling.

CM03 is a G-quadruplex-binding compound that potently inhibits cell growth in PDAC cell lines (MIA PaCa-2 IC50=19 nM).

CM-675 (CM675) is a potent, dual PDE5 and classI-HDAC inhibitor with IC50 of 114/673 nM for PDE5A/HDAC1, respectively.

CMA-008 is a cell-permeable, small molecule modulator of NAADP-mediated Ca2+ release, competes with NAADP binding, inhibit Ca2+ release via the NAADP receptor (IC50=15 uM-1 mM).

CMC2.24 (TRB-N0224) is a novel tricarbonylmethane agent that inhibits the Ras-RAF-MEK-ERK pathway, inhibits Ras activation in pancreatic cancer both in vitro and in vivo.

c-Met inhibitor 1 is an inhibitor of the c-Met receptor signaling pathway useful for the treatment of cancer including gastric, glioblastoma, and pancreatic cancer.

CMK is a RSK2 kinase inhibitor.

CMP-5 (PRMT5-IN-5)is a first-in-class, small-molecule PRMT5-specific inhibitor that blocks EBV-driven B-lymphocyte transformation and survival, without effect on normal B cells.

CMP-5 (PRMT5-IN-5)is a first-in-class, small-molecule PRMT5-specific inhibitor that blocks EBV-driven B-lymphocyte transformation and survival, without effect on normal B cells.

CMPD167 (MRK-1) is an orally acitve small molecule that binds to CCR5 to inhibit gp120 association, inhibits different stages of the virus-cell attachment and entry process (CCR5-using virus SHIV-162P3, IC50<1 nM)..

CMPDA is a potent positive allosteric modulator of GluR2 receptors with EC50 of 45.4 and 63.4 nM at GluR2i and GluR2o respectively, in a calcium influx screening assays.

CN750 (CN-750) is novel BRD4 (BD1, 2) inhibitor with IC50 of 44 nM, MV4-11 IC50 of 0.54 uM.

CNP-AFU (2-Chloro-4-nitrophenyl α-L-fucopyranoside) is a substrate for alpha-L-fucosidase(AFU).

CNS 7056 is a new short-acting sedative/anaesthetic that acts on GABAA receptors in the brain.

CN-SAH is a potent and selective inhibitor of histone methyl transferase DOT1L with IC50 of 26 nM, displays >10-fold selectivity over DNMT1, PRMT3, PRMT5, and G9α..